Among the tested subjects, 21116 subjects (95.2%) were VCA/IgA negative, no NPC cases were observed among the seronegative subjects at the first screening and in the follow-up period of 2010–2013. This evidence concerns the gene CD79A and nasopharyngeal carcinoma.